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Natural killer (NK) cells are effector lymphocytes that are under clinical investigation for the adoptive
immunotherapy of hematologic malignancies, especially acute myeloid leukemia. Recent work in mice has
identiﬁed innate memory-like properties of NK cells. Human NK cells also exhibit memory-like properties,
and cytokine-induced memory-like (CIML) NK cells are generated via brief preactivation with IL-12, IL-15, and
IL-18, which later exhibit enhanced functionality upon restimulation. However, the optimal cytokine re-
ceptors and signals for maintenance of enhanced function and homeostasis after preactivation remain
unclear. Here, we show that IL-12, IL-15, and IL-18 preactivation induces a rapid and prolonged expression of
CD25, resulting in a functional high-afﬁnity IL-2 receptor (IL-2Rabg) that confers responsiveness to picomolar
concentrations of IL-2. The expression of CD25 correlated with STAT5 phosphorylation in response to pico-
molar concentrations of IL-2, indicating the presence of a signal-competent IL-2Rabg. Furthermore, picomolar
concentrations of IL-2 acted synergistically with IL-12 to costimulate IFN-g production by preactivated NK
cells, an effect that was CD25 dependent. Picomolar concentrations of IL-2 also enhanced NK cell proliferation
and cytotoxicity via the IL-2Rabg. Further, after adoptive transfer into immunodeﬁcient NOD-SCID-gc/mice,
human cytokineepreactivated NK cells expand preferentially in response to exogenous IL-2. Collectively,
these data demonstrate that human CIML NK cells respond to IL-2 via IL-2Rabg with enhanced survival and
functionality, and they provide additional rationale for immunotherapeutic strategies that include brief
cytokine preactivation before adoptive NK cell transfer, followed by low-dose IL-2 therapy.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Natural killer (NK) cells are a subset of innate lymphoid
cells critical for host antiviral defense andmediate antitumor
immunity [1-5]. NK cells are of clinical interest and are being
explored as antitumor effectors in the allogeneic hemato-
poietic stem cell transplantation (HSCT) setting as well as an
adoptive cellular therapy of hematologic disease [6-8]. Initial
reports in the MHC-haploidentical transplantation setting
indicated that NK cells may be harnessed for graft-versus-
leukemia effects in the absence of graft-versus-host disease
[9]. Subsequent studies have investigated the molecular
basis of killer-cell immunoglobulin-like receptor genetics
and their MHC class I ligands on NK cell functional responses
and outcomes after allogeneic HSCT [10-12]. These studies
highlight the importance of integrating new advances in
basic NK cell biology, such as education and licensing, when
applying NK cells as therapeutics in the HSCT or adoptive
transfer setting.dgments on page 472.
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14.01.006NK cells are traditionally classiﬁed as innate immune
lymphocytes because they do not rearrange germline DNA to
form a dominant clonal activation receptor, distinct from T
and B cells. However, this paradigm has recently been chal-
lenged by several groups identifying innate memory medi-
ated by mouse NK cells [13] in the setting of hapten-based
sensitization [14], viral (murine cytomegalovirus [MCMV])
infection [15], and after cytokine activation with IL-12, IL-15,
and IL-18 [16]. Notably, NK cell memory that occurs after
MCMV infection depends on proinﬂammatory cytokines [17],
suggesting a common mechanistic link between virus- and
cytokine-induced NK cell memory. Studies in humans have
also shown that viral infection, in particular, human cyto-
megalovirus, results in imprinting on the NK cell compart-
ment via altering the expression patterns of NKG2C and
killer-cell immunoglobulin-like receptors that correlate
with NK cell functional status. These studies include cyto-
megalovirus reactivation after solid organ transplantation
and HSCT, which may correlate with murine virus-induced
memory NK cells [18,19]. Human NK cell memory-like
responses have been directly demonstrated in vitro after
cytokine activation with IL-12, IL-15, and IL-18 [20]. A brief
(16 hour) preactivation with IL-12, IL-15, and IL-18, followed
by rest in vitro for 1 to 6 weeks, resulted in enhanced func-
tionality, including IFN-g production after restimulationwith
cytokines or exposure to leukemia targets. This enhancedTransplantation.
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sent in peripheral blood (CD56bright and CD56dim). IL-15 was
used as a survival cytokine during the in vitro rest period
based on prior studies; however, additional cytokines that
may contribute to the homeostasis and enhanced function of
such cytokine-induced memory-like (CIML) NK cells have
not been reported. Recent work has shown that murine IL-
12, IL-15, and IL-18 preactivated NK cells have an enhanced
ability to control tumor cell line challenge, which in vivo in
mice required T cellederived IL-2 [21].
We, therefore, investigated the expression of CD25, a key
component required to form the high-afﬁnity heterotrimeric
IL-2Rabg on human NK cells brieﬂy activated with combi-
nations of IL-12, IL-15, and IL-18. NK cells constitutively ex-
press 2 components of the high-afﬁnity IL-2R: the IL-2/15Rb
and gc, which form an intermediate afﬁnity heterodimer that
transduces signals in the presence of nanomolar concentra-
tions of IL-2 or IL-15. In contrast, the heterotrimeric high-
afﬁnity IL-2Rabg (including IL-2Ra, CD25) is ligated by
picomolar concentrations of IL-2, and thus CD25 expression
dictates high-afﬁnity IL-2 binding on NK cells [22,23]. Pre-
vious work has demonstrated constitutive, low-density
expression of CD25 on CD56bright NK cells, facilitating cross
talk with Tcells and antigen presenting cells [24]. In addition,
several studies have shown that IL-2 or IL-15 stimulation
alone result in transient (hours to days) CD25 expression on
the majority of NK cells [25,26]. Here, we report that short-
term (16 hour) combined cytokine activation of human NK
cells with IL-12, IL-15, and IL-18 induced robust and pro-
longed CD25 expression that persisted for at least 7 days on
CIML NK cells. This CD25 expression resulted in a signal-
competent high-afﬁnity IL-2Rabg that stimulated STAT5
phosphorylation in NK cells. Moreover, picomolar concen-
trations of IL-2, acting via the IL-2Rabg costimulated IFN-g
production, enhanced cytotoxicity, and induced proliferation
of NK cells. Furthermore, IL-12, IL-15, and IL-18 preactivated
NK cells adoptively transferred into immunodeﬁcient NOD-
SCID-gc/ (NSG) mice were selectively supported by exoge-
nous rhIL-2. These ﬁndings provide a clear rationale for
utilizing low-dose IL-2 therapy as 1 method to support CIML
NK homeostasis and functionality cells after adoptive trans-
fer of IL-12, IL-15, and IL-18 preactivated allogeneic NK cells.
MATERIALS AND METHODS
Reagents
The following antihuman mAbs were used: Beckman Coulter (Brea,
California): CD56(N901), CD3(UCHT1); BD (Franklin Lakes, NJ): CD16(3G8),
IFN-g(B27), CD25(M-A251), pSTAT5(pY694); puriﬁed anti-CD25 (B-B10,
eBioscience, San Diego, CA) or isotype IgG1k (Biolegend, San Diego, CA). The
following endotoxin-free cytokines were used: rhIL-2 (Chiron, Emeryville,
CA); rhIL-15 (CellGenix, Freiburg, Germany); rhIL-12, rhIL-18 (Peprotech,
Rocky Hill, NJ). The K562 (ATCC, Manassas, VA) cell line was maintained in
RPMI-1640 plus 10% FCS and supplements FCS and supplements [20].
NK Cell Puriﬁcation and Cell Culture
Anonymous human platelet apheresis donor peripheral blood mono-
nuclear cells (PBMCs) were isolated by ﬁcoll centrifugation. NK cells were
puriﬁed to >95% CD56þCD3- purity using Rosettesep enrichment (StemCell
Technologies, Vancouver, Canada) as described [20]. In some experiments,
CD56dim NK cells were isolated by ﬂow cytometric sorting (>99% pure). NK
cells were cultured at 5  106/mL in complete RPMI-1640 media (Hyclone,
Logan, UT) with 10% human AB serum (Sigma, Saint Louis, MO) and sup-
plements [20].
Assays to Assess CD25 Expression and Functions
Puriﬁed NK cells were preactivated for 16 hours with individual cyto-
kines or combinations for 16 hours, washed 3 times, and replated in IL-15
(1 ng/mL) for 2 or 6 additional days. At each time point, cells were har-
vested and assessed for CD25 expression by ﬂow cytometry. For pSTAT5experiments, cells were stimulated with varying concentrations of IL-2 for
15 minutes and then stained for pSTAT5 as described [20]. In some experi-
ments, cells were preincubated for 1 hour at 37C with either an isotype or
anti-CD25 antibody (10 mg/mL). Preactivated cells were restimulated after
3 days of in vitro culture with varying concentrations of IL-2, with or
without IL-12. Cells were incubated for 6 hours in the presence of BFA/
monensin (BD) and assayed for intracellular IFN-g [20].
Flow Cytometric Analysis
Cell staining was performed as described [20,27], and data were ac-
quired on a Gallios ﬂow cytometer (Beckman Coulter) and analyzed using
FlowJo (TreeStar, Ashland, OR) or Kaluza (Beckman Coulter) software.
Phospho-STAT5 ﬂow cytometry assays were performed following the
manufacturer’s instructions (BD).
Flow-Based Killing Assay
Sorted CD56dim NK cells were preactivated for 16 hours, washed 3 times,
and then cultured in cytokine-free media for 2 days. Cells were then
cultured for an additional 24 hours, with or without the addition of IL-2,
before harvesting for use as effectors in cytotoxicity assays. Flow-based
killing assays were performed by coincubation with CFSE-labeled
K562 cells for 4 hours and assaying 7-AAD uptake as described [28]. Spon-
taneous background K562 death (no effector control wells) was subtracted
to yield percent speciﬁc killing, and in all cases was less than 5%. Flow-based
killing assay results consistently correlate with 51Cr release assays and
provide a direct method to count individual dead target cells [28,29].
In Vitro Proliferation and Survival Assays
CFSE-labeled, sorted CD56dim NK cells were preactivated and cultured in
IL-2econtaining media, with media and cytokine changes every other day.
On day 7, cells were harvested and assessed for CFSE-dilution staining or
7-AAD by ﬂow cytometry.
Human NK Cell Xenograft Experiments
Puriﬁed human NK cells were preactivatedwith IL-12, IL-15, and IL-18 or
1 ng/mL IL-15 alone (control) for 16 hours and washed 3 times, and then
equivalent numbers of control or CIML NK cells from the same donor were
transferred retro-orbitally into groups of NSG mice (3  106/mouse to
8  106/mouse). Mice were injected with rhIL-2 (75,000 IU/mouse) every
other day  3 doses. On day 7, mice were sacriﬁced and human cells were
identiﬁed with human CD45 and CD56/CD16 expression, and all human
CD45þ cells were NK cells. The relative abundance of NK cells was deter-
mined by calculating the ratio of mouse CD45 to human CD45 positive cells
in the spleen, to control for variable absolute leukocyte numbers in different
NSG mice.
Statistical Analysis
Statistical comparisons were performed using Student t-test or ANOVA
(*P < .05; **P < .005; ***P < .0005), where appropriate.
RESULTS
Induction of CD25 on IL-12, IL-15, and IL-18 Preactivated
Human NK Cells
We hypothesized that combinations of IL-12, IL-15, and
IL-18 stimulate NK cells to express CD25, thereby acquiring
responsiveness to low concentrations of IL-2. To test this
premise, cytokines known to bind to constitutively ex-
pressed cytokine receptors on resting NK cells were evalu-
ated for the ability to induce cell surface CD25 expression.
Puriﬁed human NK cells were cultured overnight in IL-2, IL-
12, IL-15, IL-18, or combinations of these cytokines. Low-dose
IL-15 (LD15) was used as a control to maintain survival. At
16 hours, all cytokines tested, with the exception of LD15,
resulted in increased expression of CD25 on both CD56dim
and CD56bright NK cells. However, these stimuli resulted in
varying percentages of CD25þ NK cells, which also varied
markedly in expression density on a per cell basis (Figure 1).
Stimulation with IL-2 or IL-12 alone modestly increased the
percentage of CD25þ NK cells, but the expression of per cell
CD25 (MFI) was low (Figure 1B,C). IL-15 or IL-18 alone
enhanced the percentage of NK cells expressing CD25, but
again resulted in a small increase in per cell expression
Figure 1. CD25 expression is induced on human NK cells by combined cytokine activation. Freshly puriﬁed human NK cells were stained for baseline CD25 expression
and activated overnight with the following cytokines (1 ng/mL IL-15, LD15; 1 nM IL-2; 100 ng/mL IL-15; 10 ng/mL IL-12; 50 ng/mL IL-18) or combinations of the
cytokines as indicated. After culture for 16 hours, cells were washed extensively and cultured for an additional 3 or 7 days in LD15 for all later time points. (A) Cell
surface CD25 is induced after activation with IL-12, IL-15, and IL-18, compared with LD15, on NK cells. Representative ﬂow histograms at baseline, 16 hours, 3 days, or
7 days after the initiation of IL-12, IL-15, and IL-18 preactivation or culture in LD15, demonstrating the marked increase and prolonged expression of CD25. (B and C)
CD25 percentage (B) and mean ﬂuorescence intensity (MFI) (C) of NK cells at various time points after cytokine activation. Summary data represent n ¼ 6 donors
(3 independent experiments). Data shown are mean  SEM of percentage or the MFI of CD25þ NK cells. Signiﬁcance is shown comparing each time point versus fresh
(baseline) NK cells, and was calculated by 1-way ANOVA. These data show that although individually IL-2, IL-12, IL-15, and IL-18 induce CD25þ CD56dim NK cells, the
combinations of IL-15þIL-18 and IL-12þIL-18 result in higher per cell CD25 expression.
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15 and IL-18, with or without IL-12, resulted in the highest
induction of CD25 per cell on NK cells (16-fold increase in
MFI, Figure 1A-C). Withdrawal of cytokine stimulation after
16 hours resulted in decreased CD25 expression over the
course of 7 days, although a large fraction of CD25þ cells
persisted after preactivation with IL-15 plus IL-18 or IL-12
plus IL-18, or IL-12 plus IL-15 plus IL-18, stimuli that have
previously been reported to induce human CIML NK cells
[20]. We also observed increased expression of CD25 by both
CD56bright and CD56dim NK cells, but notably, the MFI in-
crease in CD56dim NK equaled or exceeded that of CD56bright
NK cells in every cytokine condition tested (data not shown).
Similar results were seenwith NK cells culturedwithin PBMC
(Supplemental Figure 1). Because CD25 is not expressed in
freshly isolated CD56dim NK cells, and is at a low density on
CD56bright NK cells, we evaluated whether the mechanism of
induction of CD25 was at the IL2RA (CD25) mRNA level.
There was a marked increase in IL2RAmRNA in NK cells after
stimulation (Supplemental Figure 2), suggesting that themechanism of increased CD25 expression is primarily to
enhance transcription or stability of CD25 mRNA. Thus, NK
cells preactivated with the combination of cytokines that
induce CIML NK cells also express CD25 for a prolonged time
period, which may facilitate responsiveness to low concen-
trations of IL-2.
CD25 Induced on NK Cells by Cytokines Results in a
Signal-Competent IL-2Rabg
CD25 associates with the intermediate-afﬁnity IL-2Rbg
subunits to form the high-afﬁnity heterotrimeric IL-2Rabg
[22,30]. In response to ligationwith IL-2, this complex signals
through the IL-2Rbg chains, resulting in phosphorylation of
STAT5 [22,23]. We, therefore, evaluated whether cytokine-
activated NK cells exhibited increased phospho-STAT5
when stimulated with picomolar concentrations of IL-2,
which selectively ligate the high-afﬁnity IL-2Rabg. In these
experiments, we focused on preactivation cytokine combi-
nations that result in CIML NK cells and themost pronounced
induction of CD25: IL-15 plus IL-18 (also allowing assessment
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(Figure 1). NK cells were preactivated for 16 hours with
low doses of IL-15 (LD15, control), IL-12 plus IL-18, or IL-15
plus IL-18, washed, and rested in medium alone for an
additional 2 days to allow the NK cells to return to a baseline
state, but with maintained expression of CD25 (Figure 1).
These rested NK cells were then evaluated for their ability
to phosphorylate STAT5 in response to varying concentra-
tions of IL-2. In these assays concentrations of 10 to 100 pM,
IL-2 selectively activate IL-2Rabg, whereas 1 nM IL-2 also
activates the constitutively expressed intermediate afﬁnity
IL-2Rbg [23]. NK cells that were preactivated with IL-12 plus
IL-18 or IL-15 plus IL-18 demonstrated increased STAT5
phosphorylation beginning at 10 pM IL-2, compared
with  100 pM IL-2 required to induce pSTAT5 in control
LD15 preactivated NK cells (Figure 2). Thus, cytokine-
induced CD25 expression on NK cells results in signaling in
response to picomolar concentrations of IL-2, indicating
the presence of signal-competent heterotrimeric IL-2RabgFigure 2. Picomolar concentrations of IL-2 induce phospho-STAT5 expression in pr
IL-12þIL-18, or IL-15þIL-18, washed extensively, and replated in cytokine-free media
concentrations for 15 minutes and levels of phospho-STAT5 were analyzed by intracel
the mean  SEM percentage pSTAT5 positive CD56dim NK cells from n ¼ 3 donors an
enhanced STAT5 phosphorylation over control. Signiﬁcance was calculated by ANOVAcomplexes. We next evaluated whether such signals result in
enhanced NK cell function.
Signals via the Induced IL-2Rabg on Costimulate IFN-g
Production
In resting CD56bright NK cells, CD25 is required for pico-
molar concentrations of IL-2 to act in concert with IL-12 for
IFN-g production [24]. In contrast, resting CD56dim NK cells
fail to produce IFN-g in response to picomolar concentrations
of IL-2 plus IL-12. Because both CD56bright and CD56dim NK
cells exhibit memory-like properties, we evaluated the
ability of low-dose IL-2 to costimulate IFN-g production in
these NK cell subsets after combined cytokine induction of
CD25. In these experiments, puriﬁed NK cells were pre-
activated with cytokine combinations that result in CIML NK
cells [20] and CD25 induction (IL-12 plus IL-18 or IL-15 plus
IL-18) for 16 hours, washed, and then rested for 2 days in
cytokine-free media to allow the NK cells to return to a
baseline state (not producing IFN-g protein). In the setting ofeactivated NK cells. Puriﬁed NK cells were preactivated with LD15 (control),
for 2 days to allow recovery to a resting state. IL-2 was added at the indicated
lular ﬂow cytometry. Shown is 1 representative donor (A), or summary data of
d experiments (B). Preactivated NK cells respond to 10 and 100 pM IL-2 with
.
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NK cells producing IFN-g in response to IL-2 alone, indicating
that prior cytokine activation primes an enhanced IFN-g
response to individual cytokines (Supplemental Figure 3)
[20]. Similarly, a modest fraction of preactivated NK cells
produce IFN-g in response to IL-12 alone, again due to theFigure 3. Induced CD25 on preactivated NK cells results in a functional high-afﬁnity
activated for 16 hours with IL-12þIL-18 or IL-15þIL-18, washed extensively, and repla
was then added at the indicated doses in combination with IL-12 (1.25 ng/mL). After 6
ﬂow cytometric plots from 1 preactivated donor depicting dose-dependent IFN-g p
IL-15þIL-18 preactivated NK cells that were subgated based on CD25 expression and IF
of preactivated CD56dim NK cell IFN-g productionwith IL-12 combined with various do
(D) In a separate assay, cells were pretreated for 1 hour with either an anti-CD25ebloc
IL-12 and 10-fold dilutions of IL-2. In (B,C), data are shownwith the maximum IFN-g po
percentages between donors are variable (range of maximum %IFN-gþ:14% to 66% fo
Signiﬁcance was calculated by ANOVA.initial preactivation (0 pM IL-2, Figure 3C). When IL-2 and
IL-12 were combined, concentrations of 10 or 100 pM IL-2
were able to signiﬁcantly costimulate IFN-g production in
cytokine-preactivated NK cells. Concentrations above 100
pM failed to further increase IFN-g production, suggesting
that additional signaling via intermediate afﬁnity IL-2RbgIL-2Rabg that signals for enhanced IFN-g production. Puriﬁed NK cells were
ted in cytokine-free media for 2 days to allow recovery to a resting state. IL-2
hours, IFN-g was measured by intracellular ﬂow cytometry. (A) Representative
roduction costimulated by picomolar IL-2. (B) Representative ﬂow plots from
N-g expressionwith stimulation by IL-12 þ 1 or 100 pM IL-2. (C) Summary data
ses of IL-2, shown as mean  SEM normalized IFN-g percentage (n ¼ 4 donors).
king antibody or IgG1 isotype control, followed by stimulation with 1.25 ng/mL
sitive percentage in each donor (n ¼ 4) normalized to 100%, as absolute IFN-gþ
r IL-12þIL-18 preactivated cells, 28% to 86% for IL-15þIL-18 preactivated cells).
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NK cells that were not preactivated with cytokines but were
cultured in medium alone (ie, 72 hours in medium only)
excluded trypan blue and 7-AAD but failed to produce IFN-g,
even in response to established costimulatory conditions in
resting CD56dim NK cells (eg, 1 nM IL-2 plus IL-12) [31], likely
due to prolonged growth factor starvation (data not shown).
Therefore, we cultured NK cells in low-dose IL-15 (1 ng/mL),
which preserves the functionality of these cells but does
not induce CD25 expression (Figure 1B,C). Low-dose IL-
15eactivated cells did not produce increased IFN-g with
addition of IL-12 and IL-2, with the exception of 1nM IL-2
(Figure 3C). Thus, low concentrations of IL-2 stimulate and
costimulate (in cooperation with IL-12) IFN-g production by
combined cytokine-preactivated NK cells. We next evaluated
the absolute requirement for CD25 and the high-afﬁnity
IL-2Rabg for these IL-2 effects.
IFN-g Production in Response to Picomolar
Concentrations of IL-2 Requires CD25 and the
High-afﬁnity IL-2Rabg
Selective responsiveness to 10 to 100 pM IL-2 suggests
action through the high-afﬁnity IL-2Rabg. Furthermore,
increased CD25 inductionmediated by IL-15þIL-18 versus IL-
12þIL-18 enhanced IL-2ecostimulated IFN-g production
(mean 53% versus 32%, P < .05), and populations that
expressed more CD25 per cell also produced more IFN-g
(Figure 3B). However, to deﬁnitively establish the require-
ment for CD25 and high-afﬁnity binding, we used a blocking
anti-CD25 mAb. This approach selectively blocks the for-
mation of the high-afﬁnity IL-2Rabg because CD25 is not
available to the complex, but it allows stimulation via the
intermediate-afﬁnity IL-2Rbg. The enhanced IFN-g produc-
tion in response to 10 or 100 pM IL-2 by cytokine-
preactivated NK cells was abrogated by preincubation with
an anti-CD25 mAb (Figure 3D). In contrast, 1 nM IL-2 cos-
timulated IFN-g production regardless of CD25 blockade.
Collectively, these data indicate that picomolar concentra-
tions of IL-2, signaling through an induced IL-2Rabg, stim-
ulate enhanced IFN-g in preactivated NK cells.
Picomolar Concentrations of IL-2 Act via IL-2Rabg to
Augment Cytotoxicity by Cytokine-Preactivated NK Cells
Resting CD56dim NK cells mediate cytotoxicity when
triggered by the appropriate target cell [1,32]. We hypothe-
sized that similar to the IFN-g results, picomolar concentra-
tions of IL-2 would augment preactivated NK cell
cytotoxicity. To investigate this, we preactivated CD56dim NK
cells with low-dose IL-15, IL-12 plus IL-18, or IL-15 plus IL-18
for 16 hours; rested these cells in medium only (without
IL-2) for 48 hours; and then stimulated them with varying
concentrations of IL-2. After 24 hours, a standard ﬂow-based
cytotoxicity assay was performed with K562 leukemia cells
as targets. Consistent with observations from the IFN-g ex-
periments, we observed signiﬁcantly enhanced killing with
10 pM IL-2 stimulation, an effect that was prevented by
preincubation with an anti-CD25 antibody (Figure 4). Not-
ably, incubationwith 1 nM IL-2 failed to enhance cytotoxicity
above levels induced by 10 pM IL-2 in preactivated CD56dim
NK cells, consistent with expression of IL-2Rabg and satu-
ration of IL-2 signaling. Low-dose IL-15eactivated NK cells
had enhanced killing only when cultured with 1 nM IL-2.
Importantly, CD25 blockade abrogated enhanced cytotox-
icity in response to picomolar concentrations of IL-2, but not
at 1 nM, suggesting that the intermediate-afﬁnity IL-2Rbgwas being utilized at this IL-2 concentration. In each pre-
activation condition, the observed killing was dependent on
the effector to target ratio, as expected (Figure 4D,E and
Supplemental Figure 4).Low Concentrations of IL-2 Facilitate Cytokine-activated
NK Cell Proliferation via the IL-2Rabg
T cell secretion of IL-2 acts in an autocrine or paracrine
capacity to induce activated T cell proliferation [23]. Addi-
tionally, activated mouse NK cells, either in the context of
in vivo viral infection or in vitro cytokine stimulation, un-
dergo substantial proliferation [4,33]. Resting CD56dim NK
cells have been characterized as less proliferative compared
with CD56bright NK cells after cytokine stimulation [1,34-36];
however, proliferation by CD56dim NK cells after combined
cytokine preactivation has been observed [20]. We evaluated
whether combined cytokine-activated CD56dim NK cells
proliferated in response to low doses of IL-2 using the high-
afﬁnity IL-2Rabg. Flow-sorted CD56dim NK cells were labeled
with CFSE and preactivated with low-dose IL-15, IL-12 plus
IL-18, or IL-15 plus IL-18. After 16 hours, the cells were
washed and incubated with anti-CD25 or isotype control
mAbs for 1 hour. After this blockade, IL-2 was supplemented
at the indicated concentrations. In medium only (without
IL-2, IL-15, or other cytokines), we observed minimal prolif-
eration (Figure 5A). However, with IL-2 added at 10 pM or
greater, CD56dim NK cells were induced to proliferate in a
dose-dependent manner (Figure 5A-C). Furthermore, when
cells were precultured with an anti-CD25eblocking anti-
body, the proliferation induced by low-dose IL-2 (10 to 100
pM) was abrogated (Figure 5B,C). We observed substantial
donor-dependent variability in the degree of proliferation by
CD56dim NK cells as demonstrated in Figure 5B and C, pre-
sumably due to reported differences in the proliferative ca-
pacity of human NK subsets [37-39]. However, all donors
displayed a signiﬁcant enhancement in proliferation with
10 pM IL-2 stimulation, as well as abrogation of this
signaling after CD25 blockade.IL-2 Supports Cytokine-Preactivated CIML NK Cells
in vivo in NSG Mice
Preactivation of human NK cells with IL-12, IL-15, and IL-
18 for 16 hours followed by prolonged culture in vitro with
IL-15 for survival results in CIML NK cells. Based on the in-
duction of a functional IL-2Rabg on preactivated NK cells, we
hypothesized that rhIL-2would selectively support cytokine-
preactivated (IL-12, IL-15, IL-18) compared with control- (IL-
15 only) activated NK cells in vivo. Cytokine-preactivated or
control NK cells were generated from the same donor and,
after extensive washing, were transferred into NSGmice, and
rhIL-2 was administered every other day. After 1 week, mice
were analyzed for human NK cell numbers and evaluated for
CIML NK cell recall responses. Cytokine-preactivated NK cells
had signiﬁcantly improved engraftment in NSG mice in this
system, compared with control (IL-15) NK cells (Figure 6).
Both CD56bright and CD56dim NK cells were identiﬁed, and
enhanced recall functionality to cytokine or tumor tar-
getebased restimulation by CIML NK cells was also evident
ex vivo. These data suggest that administration of rhIL-2 after
adoptive transfer of IL-12, IL-15, and IL-18epreactivated NK
cells is a novel approach to administer and support function-
enabled NK cells as adoptive immunotherapy for patients
with hematologic malignancies.
Figure 4. Low concentrations of IL-2 enhance preactivated CD25þ CD56dim NK cell killing of K562 leukemia target cells. Flow-sorted CD56dim NK cells were pre-
activated with LD15, IL-12þIL-18, or IL-15þIL-18, washed, and replated in cytokine-free media for 2 days. Cells were then incubated for 1 hour with an isotype or anti-
CD25eblocking antibody before activation with dilutions of IL-2. After 24 hours, cells were harvested and plated in a 4-hour in vitro ﬂow-based killing assay with
CFSE-labeled K562 cells. Shown is mean  SEM percent speciﬁc killing at a 4:1 effector to target ratio preincubated with (A) an isotype control or (B,C) an anti-CD25e
blocking antibody. (D,E) Killing by preactivated CD56dim NK cells is NK cell dose- (effector to target ratio) dependent, shown at 10 pM IL-2, with anti-CD25 or isotype
control preincubation. Data are summarized from 3 to 5 donors in 2 independent experiments.
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Freshly isolated human CD56dim NK cells are thought to
require high concentrations of IL-2 (or IL-15), signaling
through the IL-2/15Rbg, to enhance or prime their functional
capacity through this receptor complex. Here, we show that
combined cytokine activation of both CD56bright and CD56dim
NK cells with IL-15 plus IL-18 or IL-12 plus IL-18 results in
robust CD25 expression, which remains present on CIML NKcells after 7 days. This CD25 expression combines with
constitutively present IL-2/15Rb and gc to form a functional
high-afﬁnity IL-2Rabg on preactivated NK cells. Such NK cells
have increased STAT5 phosphorylation when restimulated
with picomolar concentrations of IL-2 and exhibit aug-
mented functional responses, including IFN-g production,
cytotoxicity, and proliferation. Further, IL-2 supports
cytokine-preactivated NK cells in vivo in NSG xenograft
Figure 5. Low concentrations of IL-2 stimulate the proliferation of preactivated CD56dim NK cells. CFSE-labeled, ﬂow-sorted CD56dim NK cells were preactivated with
low-dose IL-15, IL-12þIL-18, or IL-15þIL-18 for 16 hours, washed extensively, and blocked with an isotype or anti-CD25eblocking antibody. Dilutions of IL-2 were
then added, with subsequent media, cytokine, and blocking antibody additions occurring every other day. After 7 days, cells were harvested and analyzed for CFSE
dilution by ﬂow cytometry. Analysis was restricted to live cells by 7-AAD exclusion. (A) Data shown represent histograms from 1 donor. Both isotype-blocked (open
histograms) and anti-CD25eblocked (shaded histograms) NK cell proliferation are shown. (B and C) Summary data depicting the variability of proliferation between
IL-12þIL-18 or IL-15þIL-18 activated CD56dim NK cells from different donors and the dependence of picomolar IL-2 mediated proliferation on CD25/IL-2Rabg.
Signiﬁcance was assessed by 2-way ANOVA.
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(CD56bright and CD56dim) are induced to express IL-2Rabg
after combined cytokine preactivation, expanding the po-
tential of low concentrations of IL-2 to stimulate and support
CIML NK cells. These data suggest that low-dose IL-2 therapy
can support survival, proliferative, and effector functions of
IL-12, IL-15, and IL-18epreactivated allogeneic NK cells after
adoptive transfer.
What role does the high-afﬁnity IL-2Rabg on CD56dim NK
cells play during a physiologic immune response? During thehost response to a pathogen, NK cells have a complex set of
interactions with other members of the innate and adaptive
immune system [2,40,41]. After infection with MCMV, a
model virus infection with a prominent early NK cell
response, an initial wave of cytokines are produced that drive
NK cell proliferation and enhances their functional capacity.
In this setting, IL-12, IL-15, and IL-18 are induced over 1 to
2 days, a time frame consistent with the induction of CD25
on mouse NK cells [42,43]. In a recent report from the Biron
laboratory, induced CD25 was identiﬁed on NK1.1þTCRb- NK
Figure 6. Exogenous IL-2 supports CIML NK cells in a NSG xenograft model. (A) Puriﬁed human NK cells were preactivated with IL-12, IL-15, and IL-18 (CIML) or low-
dose IL-15 only (control) for 16 hours, washed, and identical numbers of NK cells were transferred into NSG mice, followed by injections of 75,000 IU i.p. of rhIL-2
every other day. After 7 days, mice were assessed for human NK cell content and CIML NK cell recall responses. (B) Representative ﬂow plots from the peripheral
blood of mice injected with the same number of CIML or control NK cells from the same donor 7 days earlier. Human CD45þ cells are CD56þCD3- NK cells with
preserved CD56bright and CD56dim NK cells subsets. (C) Summary data from 3 different NK cell donors transferred into a total of 12 NSG mice demonstrating superior
engraftment of CIML, compared with control NK cells. The ratio of human to mouse CD45þ cells, representing the relative abundance of human NK cells, is used to
control for differences in blood volume obtained. (D) Mouse splenocytes containing adoptively transferred human NK cells were evaluated for a recall IFN-g response
after IL-12þIL-15 restimulation, demonstrating that CIML NK cells exhibit preserved, enhanced functionality in this xenograft model. Signiﬁcance was assessed by
t-test, with *P < .05, **P < .01, and ***P < .001.
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In vitro, NK cells within bulk murine splenocytes were
induced to express CD25 after 24 hours by the combination
of IL-12 plus IL-18, which absolutely required IL-12-induced
STAT4 signals [43]. Thus, we suspect that during human re-
sponses to viruses and potentially other pathogens, IL-12, IL-
15, and IL-18 are produced, and CD56dim NK cells are induced
to express CD25 (Supplemental Figure 5). In our studies, we
identiﬁed that human NK cells are optimally stimulated by
IL-15 plus IL-18 (in the presence or absence of IL-12) to
express CD25, differing from mouse NK cell requirement forIL-12. Because all doublet combinations of IL-12, IL-15, and
IL-18 resulted in CD25 expression, human NK cells may have
an expanded ﬂexibility to express the high-afﬁnity IL-2Rabg
in different inﬂammatory cytokine responses. Notably, IL-18
appeared to be necessary, but not sufﬁcient, for substantial
CD25 expression in our experiments.
Recently, combined cytokine preactivation with IL-12, IL-
15, and IL-18 has been shown in mouse [16,21,44] and human
[20] NK cells to result in memory-like NK cell functions, with
long-lived, enhanced functionality to restimulation. CIML NK
cell function refers to NK cells that are preactivated (eg, IL-
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exhibit enhanced functional responses to a wide variety of
restimulation triggers, including cytokines, activating NK cell
receptors, or tumor cells. This was ﬁrst described in mouse
systems [16,45], and human NK cells were also found to
exhibit similar CIML responses [20]. In addition, Ly49H-
mediated “memory” NK cell function in the context of
MCMV infection was found to depend on early proin-
ﬂammatory cytokine signals [17]. For human NK cells, it is
noteworthy that the same cytokine combinations of IL-12 plus
IL-18 or IL-15 plus IL-18 that preactivate memory-like NK
functionality are also the optimal cytokine inducers of CD25
expression. Although human CIML NK cells were supported
with IL-15 in vitro after preactivation [20], low concentrations
of IL-2 may also have a role in supporting these memory-like
NK cell functions, either endogenously or exogenously [21]. In
addition, mouse IL-12, IL-15, and IL-18epreactivated NK cells
were also recently shown to effectively clearmouse tumor cell
line challenges in vivo [21]. After transfer into irradiated
syngeneic mice, NK cells were found to require CD4þ T cell
derived IL-2 in vivo to effectively eliminate lymphoma and
melanoma cell line challenges. Both murine and human NK
cells were also shown to express CD25 immediately after IL-
12, IL-15, and IL-18 activation, which is consistent with our
ﬁndings in humanNK cell subsets [21]. Thus, both human and
mouse NK cells can be induced to express CD25 and a high-
afﬁnity IL-2Rabg, which may be important to support NK
cell functional competency after viral infection or after exog-
enous IL-12, IL-15, and IL-18 preactivation.
What are the clinical implications of peripheral blood NK
cell acquisition of a functional high-afﬁnity IL-2Rabg? Allo-
geneic NK cell therapy has evidence of antileukemic activity
in clinical trials in acute myelogenous leukemia patients [46].
Low-dose or ultra-lowedose IL-2 therapy has been shown to
expand CD56bright NK cells selectively over CD56dim NK cells
in patients with HIV infection or cancer [47,48], most likely
due to lack of the high-afﬁnity IL-2Rabg on CD56dim NK cells
that promotes survival in the resting state [49]. As CD56dim
NK cells represent 80% to 95% of the mature peripheral blood
NK population, adoptive transfer of NK cells preactivated
with combinations of IL-12, IL-15, and IL-18, followed by low-
dose IL-2 therapy in vivo, may be a useful strategy to further
enhance antitumor and/or antiviral NK cell responses. Such
an approach would include strategies to limit regulatory
T cell numbers or function.
In summary, NK cells that are preactivated with combi-
nations of IL-12, IL-15, and IL-18 are induced to express CD25
and a high-afﬁnity IL-2Rabg, which persists in CIML NK cells.
This results in an acquired ability of all peripheral blood NK
cells to proliferate, kill tumor targets, and produce IFN-g in
response to picomolar concentrations of IL-2. IL-2 supports
CIML NK cells in vivo in xenograft models. Thus, our ﬁndings
provide a rationale for low-dose IL-2 therapy to enhance
expansion and NK cell function after IL-12, IL-15, and IL-
18epreactivatedNK cell adoptive transfer as immunotherapy
for cancer patients.
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